Table 2.

Validation results for the subset of patients from the 20% validation set that includes patients with pretreatment slides only (n = 931).

Clinical outcome	NCCN AUC estimates (95% CI)	MMAI AUC (95% CI)	Differential AUC estimate (MMAI - NCCN)	Comparative test p-value
Distant Metastasis (5-year)	0.72 (0.67–0.78)	0.83 (0.78–0.88)	0.11	<0.001
Distant Metastasis (10-year)	0.69 (0.64–0.74)	0.78 (0.73–0.84)	0.09	<0.001
Biochemical Failure (5-year)	0.61 (0.57–0.64)	0.69 (0.65–0.73)	0.08	<0.001
Biochemical Failure (10-year)	0.62 (0.58–0.66)	0.68 (0.63–0.72)	0.06	0.004
Prostate Cancer-Specific Survival (10-year)	0.67 (0.61–0.73)	0.77 (0.70–0.83)	0.10	<0.001
Overall Survival (10-year)	0.57 (0.54–0.61)	0.65 (0.61–0.69)	0.08	<0.001

AUC Area under the curve, CI confidence interval, MMAI multimodal artificial intelligence, NCCN National Comprehensive Cancer Network.